BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy ...
The PFIC rules tax gains and distributions at the highest applicable tax rate. They also subject U.S. taxpayers to interest charges during the period where taxation would otherwise be deferred. The ...
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced ...
On Wednesday, the IRS announced that it will amend the regulations governing the reporting requirements for U.S. persons who hold stock in passive foreign investment companies (PFICs). The amendments ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI ® (maralixibat) oral solution and tablet formulation for the ...
Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with ...
With Livmarli sales reaching $142 million during its second full year on the market, Mirum Pharmaceuticals’ rare liver disease treatment is off to a solid start in fulfilling its blockbuster potential ...
There are separate foreign tax credit rules for PFICs. Generally, non-corporate PFIC shareholders may not take advantage of foreign tax credits. 1 However, a corporate shareholder that owns 10 percent ...
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results